Cardiovascular Risk in Psoriasis: Current State of the Art

Author(s): Giuseppe Dattilo*, Francesco Borgia, Claudio Guarneri, Matteo Casale, Roberto Bitto, Claudia Morabito, Salvatore Signorelli, Niki Katsiki, Serafinello P. Cannavò.

Journal Name: Current Vascular Pharmacology

Volume 17 , Issue 1 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Psoriasis (Pso) is a chronic inflammatory immune-mediated skin disease associated with several comorbidities. Despite the growing number of studies providing evidence for the link between Pso and Cardiovascular (CV) disorders, there are still many unsolved questions, dealing with the role of the skin disease as an independent risk factor for CV events, the influence of Pso severity and duration on CV damage, the presence of Psoriatic Arthritis (PsA) as a predictor of increased CV mortality and morbidity and the detection of reliable clinical, laboratory and/or instrumental parameters to stratify CV risk in psoriatic patients. Moreover, it remains to clarify if the early treatment of the dermatosis may lower CV risk. In this paper we will try to provide answers to these queries in the light of the updated data of the literature.

Keywords: Psoriasis, cardiovascular risk, risk factors, coronary artery disease, metabolic syndrome, myocardial infarction.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [85 - 91]
Pages: 7
DOI: 10.2174/1570161115666171116163816
Price: $58

Article Metrics

PDF: 32
PRC: 1